#renaldisease

Established animal model of AKI showed a statistically significant reduction of a key biomarker of kidney injury when treated with UNI-494 AKI remains a serious unmet medical need with no FDA approved drugs for its treatment On track to…

LOS ALTOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced the acceptance of two…

Renazorb product profile rated as best-in-class phosphate binder Nephrologists report high prescribing intent for Renazorb pending FDA approval LOS ALTOS, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. …